Tuesday, July 3, 2018

Press release about a vaccine against Lyme disease

Press Release:

VALNEVA Announces Significant Progress of its Lyme Disease Vaccine Candidate

The Company has successfully concluded the end of Phase 1 process for this candidate with the Food and Drug Administration (FDA) and has obtained alignment with regard to its Phase 2 strategy.

Valneva is now finalizing the detailed Phase 2 protocol and, subject to requisite regulatory approvals, expects to enter Phase 2 clinical development by the end of 2018.

No comments:

Post a Comment

Please be constructive in your comments.